Focus: Eisai is a biotechnology company headquartered in China (Liaoning) specializing in small-molecule therapeutics across oncology, neurology, immunology, gastroenterology, and metabolic diseases. The company operates with a highly concentrated revenue model anchored by its peak-stage oncology asset LENVIMA.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Cooling — net -6 jobs in 30d
16 added, 22 removed. Slower than typical.
Eisai offers focused R&D opportunity in oncology and neurology, but extreme revenue dependency and limited scale make it a higher-risk career bet than diversified mid-caps.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company anchor asset generating 91% of revenue with extended exclusivity until 2038; represents single point of failure for corporate stability.
Help build intelligence for Eisai
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eisai's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Sleep disorder therapeutic with 12-year patent runway offering some portfolio diversification.
Mature proton-pump inhibitor facing imminent generic competition and minimal revenue contribution.
Legacy Alzheimer's therapeutic now marginalized by newer amyloid-targeting agents and facing exclusivity loss.
Minimal-revenue oncology asset with impending 2027 patent cliff.
Early-stage commercial biologic for Alzheimer's disease representing strategic entry into amyloid-targeting space with uncertain revenue trajectory.
5 discontinued, 1 duplicate formulations not shown
+2 more
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo